Galderma Unveils 2025 Aesthetic Innovations at AMWC

• Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess^® (RelabotulinumtoxinA) highlighting its rapid onset of action as early as day one and sustained high patient satisfaction beyond six months^1,2
• New in vivo data on Sculptra^® (PLLA-SCA), the first proven regenerative biostimulator, will be presented, showing its lower inflammatory response compared to PLLA-GA, which can significantly impact local tissue response and product degradation and therefore may impact the duration of clinical effect^3-12
• Additionally, results from the first-of-its-kind and largest survey on facial changes associated with medication-driven weight loss will be presented showing many patients would consider aesthetic treatments to address these changes, with biostimulators and dermal fillers the most frequently considered¹³
• Galderma will host a symposium exploring how aesthetic treatments can address facial changes associated with medication-driven weight loss in addition to a second symposium dedicated to achieving the ideal lips with Restylane^® Kysse™
• In total, Galderma will present 11 e-posters, including additional updates on Restylane, and host two symposia, four Masterclass sessions, five Meet-the-Expert sessions, an experiential lounge and an interactive booth, reinforcing its strong leadership position in Injectable Aesthetics

ZUG, Switzerland--BUSINESS WIRE--

Galderma (SWX:GALD) will showcase a strong presence at the 23^rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions. This extensive program highlights the breadth of Galderma's leading Injectable Aesthetics portfolio, designed to address the present and future needs of patients and healthcare professionals alike.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319676050/en/

Expert perspectives on the hottest topics in injectable aesthetics today

Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with alterations in facial aesthetic appearance of variable magnitude.¹⁴ In the largest study investigating facial changes in medication-driven weight loss to date, Galderma surveyed more than 1,300 people across five countries.¹³ Findings from this first-of-its kind study will be presented, showing 93% of those undergoing weight loss treatment noticed some degree of facial changes during their treatment and many patients are considering aesthetic treatments to address these, with biostimulators and dermal fillers being the most frequently considered treatments.¹³ The Galderma-sponsored "Medication-Driven Weight Loss: The Algorithms" symposium taking place on Thursday, March 27, as well as a dedicated Masterclass session on Friday, March 28, will explore the effects medication-driven weight loss can have on the face and dive into the ways aesthetic procedures can help restore facial volume and structure. The symposium will feature live demonstrations and expert insights from Dr. Luiz Avelar, Dr. Priyanka Chadha, Prof. Sebastian Cotofana, Dr. Sabrina Fabi, Dr. Marcus Morais, and Dr. Andreas Nikolis.

Galderma will also host the "GAIN Experts Dialogue: Defining the Ideal Lips" symposium on Thursday, March 27, featuring expert speakers Prof. Sebastian Cotofana, Dr. Simone Doreian, Dr. Stephanie Lam, Dr. Christoph Martschin, and Dr. Andrei Metelitsa. This session, through insightful debates, cultural and anatomical discussions, and live injection demonstrations, will explore the evolving techniques in aesthetic lip treatments as well as patient standards and preferences for natural looking and feeling results. A Masterclass session will also be held to dive deeper into these techniques on Saturday, March 29.

New data cements the unique ability of Galderma's products to meet patient needs

Galderma will present new data from the phase IIIb EXPRESSION and RELAX studies, showing Relfydess achieved rapid onset of action and significant aesthetic improvement in frown lines and crow's feet.^1,2 In the EXPRESSION study more than 50% of patients reported visible effects as early as day one and, in the RELAX study, effects were sustained through six months, confirming results seen in the READY trial program and more than a third saw improvement beyond six months in frown lines.^1,2 Both studies re-confirmed high patient satisfaction with Relfydess, with 70% of patients in the RELAX study reporting that they preferred treatment with Relfydess versus prior treatments received.^1,2 Encore data from a post-hoc analysis of the phase III READY program will show that, regardless of baseline wrinkle severity (moderate/severe), subjects treated with Relfydess achieved high rates of improvement in frown lines and crow's feet, along with improved well-being, and a sustained effect through six months.¹⁵

Galderma will also present new data on Sculptra (PLLA-SCA), the first proven regenerative biostimulator, reinforcing its unique formulation, efficacy, and safety.^3-12 New in vivo comparative data will demonstrate its favorable tissue response and slower, controlled product degradation profile at 52 weeks, as well as lower inflammation, compared to PLLA-GA.¹¹ The lower inflammation is consistent with Sculptra's well-established safety profile.³ Differences in formulation can significantly impact local tissue response and product degradation, affecting potential clinical outcomes such as efficacy and duration.¹¹ An expert consensus also confirms Sculptra's key role in the regenerative aesthetic field and additional data will show its synergistic effect when paired with Alastin^®, underscoring its effect across all three skin layers.^12,16

Encore data to be presented on Restylane Shaype™, powered by Galderma's proprietary NASHA HD™ Technology and approved in Canada and most recently in Brazil, will show that it constitutes a breakthrough innovation in hyaluronic acid fillers as the firmest hyaluronic acid injectable available and displaying the highest G-prime (indicating superior gel strength and firmness) on the market providing a unique bone mimicking effect.^17,18 Additional pooled and pivotal phase IV data to be presented will show that Restylane fillers preserve or enhance the natural expressions of 98% of patients while achieving desired aesthetic improvements in attractiveness and youthfulness.¹⁹ This naturalness, combined with high patient satisfaction, represents long-lasting aesthetic improvement.¹⁹ To date, Restylane is the first and only hyaluronic acid filler to have in vivo data demonstrating its efficacy in restoring and maintaining the naturalness of expression.^19-22

These e-posters, along with others presented on Dysport^® and Alastin, will reinforce Galderma's strong dedication to equipping practitioners with the products they need to achieve natural, long-lasting results for their patients.

More details on Galderma's scientific presentations at AMWC can be found here. Media can watch this video